skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment

Abstract

Highlights: •Most cancer types of the NCI60 have sub-sets of cell lines with high GHR expression. •GHR is highly expressed in melanoma cell lines. •GHR is elevated in advanced stage IV metastatic tumors vs. stage III. •GH treatment of metastatic melanoma cell lines alters growth and cell signaling. -- Abstract: Accumulating evidence implicates the growth hormone receptor (GHR) in carcinogenesis. While multiple studies show evidence for expression of growth hormone (GH) and GHR mRNA in human cancer tissue, there is a lack of quantification and only a few cancer types have been investigated. The National Cancer Institute’s NCI60 panel includes 60 cancer cell lines from nine types of human cancer: breast, CNS, colon, leukemia, melanoma, non-small cell lung, ovarian, prostate and renal. We utilized this panel to quantify expression of GHR, GH, prolactin receptor (PRLR) and prolactin (PRL) mRNA with real-time RT qPCR. Both GHR and PRLR show a broad range of expression within and among most cancer types. Strikingly, GHR expression is nearly 50-fold higher in melanoma than in the panel as a whole. Analysis of human metastatic melanoma biopsies confirmed GHR gene expression in melanoma tissue. In these human biopsies, the level of GHR mRNA is elevated inmore » advanced stage IV tumor samples compared to stage III. Due to the novel finding of high GHR in melanoma, we examined the effect of GH treatment on three NCI60 melanoma lines (MDA-MB-435, UACC-62 and SK-MEL-5). GH increased proliferation in two out of three cell lines tested. Further analysis revealed GH-induced activation of STAT5 and mTOR in a cell line dependent manner. In conclusion, we have identified cell lines and cancer types that are ideal to study the role of GH and PRL in cancer, yet have been largely overlooked. Furthermore, we found that human metastatic melanoma tumors express GHR and cell lines possess active GHRs that can modulate multiple signaling pathways and alter cell proliferation. Based on this data, GH could be a new therapeutic target in melanoma.« less

Authors:
 [1];  [1]
  1. Edison Biotechnology Institute, 1 Watertower Drive, Athens, OH (United States)
Publication Date:
OSTI Identifier:
22242181
Resource Type:
Journal Article
Journal Name:
Biochemical and Biophysical Research Communications
Additional Journal Information:
Journal Volume: 441; Journal Issue: 1; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0006-291X
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; ANIMAL TISSUES; BIOPSY; CARCINOGENESIS; CELL PROLIFERATION; KIDNEYS; LARGE INTESTINE; LEUKEMIA; LTH; LUNGS; MAMMARY GLANDS; MELANOMAS; MESSENGER-RNA; METASTASES; PROSTATE; RECEPTORS; STH

Citation Formats

Sustarsic, Elahu G., Department of Biological Sciences, Ohio University, Athens, OH, Junnila, Riia K., Kopchick, John J., E-mail: kopchick@ohio.edu, Department of Biological Sciences, Ohio University, Athens, OH, and Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH. Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment. United States: N. p., 2013. Web. doi:10.1016/J.BBRC.2013.10.023.
Sustarsic, Elahu G., Department of Biological Sciences, Ohio University, Athens, OH, Junnila, Riia K., Kopchick, John J., E-mail: kopchick@ohio.edu, Department of Biological Sciences, Ohio University, Athens, OH, & Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH. Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment. United States. https://doi.org/10.1016/J.BBRC.2013.10.023
Sustarsic, Elahu G., Department of Biological Sciences, Ohio University, Athens, OH, Junnila, Riia K., Kopchick, John J., E-mail: kopchick@ohio.edu, Department of Biological Sciences, Ohio University, Athens, OH, and Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH. 2013. "Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment". United States. https://doi.org/10.1016/J.BBRC.2013.10.023.
@article{osti_22242181,
title = {Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment},
author = {Sustarsic, Elahu G. and Department of Biological Sciences, Ohio University, Athens, OH and Junnila, Riia K. and Kopchick, John J., E-mail: kopchick@ohio.edu and Department of Biological Sciences, Ohio University, Athens, OH and Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH},
abstractNote = {Highlights: •Most cancer types of the NCI60 have sub-sets of cell lines with high GHR expression. •GHR is highly expressed in melanoma cell lines. •GHR is elevated in advanced stage IV metastatic tumors vs. stage III. •GH treatment of metastatic melanoma cell lines alters growth and cell signaling. -- Abstract: Accumulating evidence implicates the growth hormone receptor (GHR) in carcinogenesis. While multiple studies show evidence for expression of growth hormone (GH) and GHR mRNA in human cancer tissue, there is a lack of quantification and only a few cancer types have been investigated. The National Cancer Institute’s NCI60 panel includes 60 cancer cell lines from nine types of human cancer: breast, CNS, colon, leukemia, melanoma, non-small cell lung, ovarian, prostate and renal. We utilized this panel to quantify expression of GHR, GH, prolactin receptor (PRLR) and prolactin (PRL) mRNA with real-time RT qPCR. Both GHR and PRLR show a broad range of expression within and among most cancer types. Strikingly, GHR expression is nearly 50-fold higher in melanoma than in the panel as a whole. Analysis of human metastatic melanoma biopsies confirmed GHR gene expression in melanoma tissue. In these human biopsies, the level of GHR mRNA is elevated in advanced stage IV tumor samples compared to stage III. Due to the novel finding of high GHR in melanoma, we examined the effect of GH treatment on three NCI60 melanoma lines (MDA-MB-435, UACC-62 and SK-MEL-5). GH increased proliferation in two out of three cell lines tested. Further analysis revealed GH-induced activation of STAT5 and mTOR in a cell line dependent manner. In conclusion, we have identified cell lines and cancer types that are ideal to study the role of GH and PRL in cancer, yet have been largely overlooked. Furthermore, we found that human metastatic melanoma tumors express GHR and cell lines possess active GHRs that can modulate multiple signaling pathways and alter cell proliferation. Based on this data, GH could be a new therapeutic target in melanoma.},
doi = {10.1016/J.BBRC.2013.10.023},
url = {https://www.osti.gov/biblio/22242181}, journal = {Biochemical and Biophysical Research Communications},
issn = {0006-291X},
number = 1,
volume = 441,
place = {United States},
year = {Fri Nov 08 00:00:00 EST 2013},
month = {Fri Nov 08 00:00:00 EST 2013}
}